137 results on '"Kelly, William Kevin"'
Search Results
2. Guidelines on Germline Testing for Urologic Tumor Syndromes
3. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
4. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
5. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
6. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile
7. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials
8. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
9. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients
10. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
11. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
12. Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer.
13. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer
14. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
15. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
16. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma
17. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
18. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.
19. Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review.
20. An Internet Intervention for Management of Uncertainty During Active Surveillance for Prostate Cancer
21. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
22. Editorial Comment
23. Multicenter Phase 2 Study of Neoadjuvant Paclitaxel, Estramustine Phosphate, and Carboplatin Plus Androgen Deprivation Before Radiation Therapy in Patients With Unfavorable-Risk Localized Prostate Cancer: Results of Cancer and Leukemia Group B 99811
24. Innovations and Challenges in Prostate Cancer: Summary Statement for the 6th Cambridge Conference
25. High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?
26. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer
27. Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid
28. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
29. Histone Deacetylase Inhibitors
30. Bisphosphonates for Men With Prostate Cancer: Sifting Through the Rubble
31. Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer
32. Novel trial designs: which agents and how do we test them?
33. Overview consensus statement
34. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
35. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
36. A novel program to address acute food insecurity among patients with cancer in Philadelphia.
37. Randomized placebo-controlled trial of intravenous vitamin C plus docetaxel in metastatic prostate cancer.
38. Therapy with metronomic cyclophosphamide (mCyc) in metastatic castrate resistant prostate cancer (mCRPC) and genomic correlates.
39. Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC).
40. Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.
41. Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
42. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
43. A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
44. Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study.
45. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.
46. Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
47. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
48. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group.
49. Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity.
50. Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.